Cost-effectiveness of using a 20-valent pneumococcal conjugate vaccine to directly protect adults in England at elevated risk of pneumococcal disease
D Mendes, A Averin, M Atwood, R Sato… - Expert Review of …, 2022 - Taylor & Francis
Objectives Despite the current pneumococcal vaccination program in England for older
adults and adults with underlying conditions, disease burden remains high. We evaluated …
adults and adults with underlying conditions, disease burden remains high. We evaluated …
Pneumococcal conjugate vaccine impact on serotype 3: a review of surveillance data
HL Sings, BD Gessner, MD Wasserman… - Infectious Diseases and …, 2021 - Springer
Introduction Limited changes in serotype 3 invasive pneumococcal disease (IPD) incidence
rates after a decade of 13-valent pneumococcal conjugate vaccine (PCV13) introduction into …
rates after a decade of 13-valent pneumococcal conjugate vaccine (PCV13) introduction into …
Prevention of coronavirus disease 2019 among older adults receiving pneumococcal conjugate vaccine suggests interactions between Streptococcus pneumoniae …
Background While secondary pneumococcal pneumonia occurs less commonly after
coronavirus disease 2019 (COVID-19) than after other viral infections, it remains unclear …
coronavirus disease 2019 (COVID-19) than after other viral infections, it remains unclear …
Cost-effectiveness of 20-valent pneumococcal conjugate vaccine in Denmark compared with PPV23
J Olsen, H Schnack, M Skovdal, J Vietri… - Journal of Medical …, 2022 - Taylor & Francis
Background A new 20-valent pneumococcal conjugate vaccine (PCV20) provides protection
against 20 pneumococcal serotypes. The vaccine has the potential to decrease the impact of …
against 20 pneumococcal serotypes. The vaccine has the potential to decrease the impact of …
RSV and rhinovirus increase pneumococcal carriage acquisition and density, whereas nasal inflammation is associated with bacterial shedding
E Mitsi, E Nikolaou, A Goncalves, A Blizard, H Hill… - Cell host & …, 2024 - cell.com
Epidemiological studies report the impact of co-infection with pneumococcus and respiratory
viruses upon disease rates and outcomes, but their effect on pneumococcal carriage …
viruses upon disease rates and outcomes, but their effect on pneumococcal carriage …
Yields and immunomodulatory effects of pneumococcal membrane vesicles differ with the bacterial growth phase
M Mehanny, T Kroniger, M Koch… - Advanced …, 2022 - Wiley Online Library
Streptococcus pneumoniae infections are a leading cause of death worldwide. Bacterial
membrane vesicles (MVs) are promising vaccine candidates because of the antigenic …
membrane vesicles (MVs) are promising vaccine candidates because of the antigenic …
Effect of pneumococcal conjugate vaccines on viral respiratory infections: a systematic literature review
IT Sepúlveda-Pachón, EM Dunne… - The Journal of …, 2024 - academic.oup.com
Background In addition to preventing pneumococcal disease, emerging evidence indicates
that pneumococcal conjugate vaccines (PCVs) might indirectly reduce viral respiratory tract …
that pneumococcal conjugate vaccines (PCVs) might indirectly reduce viral respiratory tract …
Experimental human challenge defines distinct pneumococcal kinetic profiles and mucosal responses between colonized and non-colonized adults
Colonization of the upper respiratory tract with Streptococcus pneumoniae is the precursor
of pneumococcal pneumonia and invasive disease. Following exposure, however, it is …
of pneumococcal pneumonia and invasive disease. Following exposure, however, it is …
A Randomized Controlled Clinical Trial of Nasal Immunization with Live Virulence Attenuated Streptococcus pneumoniae Strains Using Human Infection Challenge
H Hill, E Mitsi, E Nikolaou, A Blizard… - American Journal of …, 2023 - atsjournals.org
Rationale: Pneumococcal pneumonia remains a global health problem. Pneumococcal
colonization increases local and systemic protective immunity, suggesting that nasal …
colonization increases local and systemic protective immunity, suggesting that nasal …
Human infection challenge with serotype 3 pneumococcus
RE Robinson, E Mitsi, E Nikolaou, S Pojar… - American journal of …, 2022 - atsjournals.org
Rationale: Streptococcus pneumoniae serotype 3 (SPN3) is a cause of invasive
pneumococcal disease and associated with low carriage rates. Following the introduction of …
pneumococcal disease and associated with low carriage rates. Following the introduction of …